A new study is set to assess the validity and reliability of the Londrina Activities of Daily Living Protocol in individuals diagnosed with idiopathic pulmonary fibrosis (IPF). The study is sponsored by Izmir Katip Celebi University, Turkey. This research will be conducted as a patient registry, with an estimated enrollment of 30 participants. Participants will…
Avalyn Pharma presented recent data from an open-label extension (OLE) study that support the potential of inhaled pirfenidone, AP01, to preserve forced vital capacity (FVC) in individuals with various forms of pulmonary fibrosis. The new data, reported at the European Respiratory Society (ERS) Congress, was derived from the ongoing AP01-005 OLE study, which followed the…
Galecto, Inc. announced results from its phase 2b GALACTIC-1 trial assessing the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis (IPF). The results did not meet the primary endpoint of a reduced rate of decline from baseline in forced vital capacity. “Going forward, we are eager to expand our focus…
Evidence suggests there might be a causal relationship between high serum adiponectin and a decreased risk of developing idiopathic pulmonary fibrosis (IPF), however, adipokines such as leptin, resistin, or monocyte chemoattractant protein-1 (MCP-1) appear unrelated to the risk of IPF, according to a study published in Lung. The researchers analyzed the summary data from genome-wide…
E1A-binding protein p300 (p300) plays a key role in the development of lung fibrosis in alveolar type II (ATII) cells, which has significant consequences for the diagnosis and treatment of patients with idiopathic pulmonary fibrosis (IPF). These findings come from a study conducted in human lung samples collected from the tissue bank of the Severance…
In patients with idiopathic pulmonary fibrosis (IPF), airway-soluble colony-stimulating factor-1 receptor (CSF1R) can play a role in predicting disease progression, according to findings from a single-center, retrospective study published in ERJ Open Research. To date, 2 antifibrotic treatments—pirfenidone and nintedanib—have demonstrated efficacy in slowing the progression of IPF; however, neither agent has the ability to…
Ambient sulfur dioxide (SO2) exposure and genetic susceptibility appear to be key risk factors for developing incident idiopathic pulmonary fibrosis (IPF), according to findings from a large-scale, national prospective cohort study conducted in China and published in the journal Chemosphere. Because effective therapies for patients with IPF are limited, it is vital to explore the…
A combination of N-acetylcysteine (NAC) and pirfenidone may be the most cost-effective option for the treatment of idiopathic pulmonary fibrosis (IPF), according to a study published in eClinicalMedicine. To evaluate the cost-effectiveness of available IPF therapies, the authors searched 8 databases for eligible randomized controlled trials published in any language between January 1, 1992, and…
A new study has demonstrated a causal link between gastroesophageal reflux disease (GERD) and the development of idiopathic pulmonary fibrosis (IPF) and other chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and chronic bronchitis. The study, published in BMC Pulmonary Medicine, suggests that a process in GERD-associated microaspiration of stomach contents might contribute…
Patient dosing with INS018_055, the first antifibrotic small molecule inhibitor discovered and designed using generative artificial intelligence (AI) for the treatment of idiopathic pulmonary fibrosis (IPF) has started, Insilico Medicine announced. The trial is part of a multiregional phase 2 clinical trial conducted in the United States and China. “With demonstrated potential against both fibrosis…
Please login or register first to view this content.
